Abstract:Antibodies to heparin-platelet factor 4 (PF4) complexes have been observed in patient with heparin-induced thrombocytopenia (HIT) syndrome. These antibodies may be of various isotypes and differ with respect to their ability to activate platelets/endothelial cells. This study determined the isotypes and functionality of antiheparin-platelet factor 4 (AHPF4) antibodies in 111 patients treated with heparin and clinically suspected for HIT. In this patient population, 50% had detectable AHPF4 cumulative IgA, IgG, and IgM (determined by enzyme-linked immunosorbent assay, ELISA), but only 35% was positive when tested with the (14)C-serotonin release assay (SRA). Using antihuman Ig specific for different isotypes, we found that 50% of the 111 samples was positive for IgG, 45% for IgM, and 37% for IgA. In 50 normal human serum (NHS) samples, only two were positive for IgG, but 33 were positive for IgM, indicating a potential humoral response to the heparin-PF4 complex prior to heparin administration. Patients that were ELISA(+) for AHPF4 antibody titer were subdivided into SRA-positive (+) and SRA-negative (-) groups. The SRA(+) group had a mean ELISA optical density (OD) for AHPF4 IgA/IgG/IgM of 2.1, while the SRA(-) group had a mean OD of 0.8 (P<.001). The SRA(+) group had greater mean OD values for all three individual isotypes. Using flow cytometry, we determined the ability of different patient samples to activate platelets. Samples that contained IgG and were SRA(+) activated platelets (as measured by microparticle generation and P-selectin expression) in the presence of therapeutic concentrations of heparin. NHS and samples containing IgA and/or IgM that were SRA(-) were not able to produce microparticles nor were they able to increase expression of P-selectin. Together, these data indicate that IgG is the principal mediator of platelet activation in patients with HIT, with IgA and IgM playing a less significant role in the pathophysiology of this syndrome.

CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer

The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder

Effect of HIT Components on the Development of Breast Cancer Cells

Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia

Platelet factor 4(PF4) and its multiple roles in diseases

Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?

PF4 Promotes Platelet Production and Lung Cancer Growth

Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG

Evolving concepts of pathogenesis of heparin-induced thrombocytopenia: Diagnostic and therapeutic implications

Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin

Protease-Activated Receptors in Cancer: A Systematic Review

Anti-PF4 ELISA-Negative, SRA-Positive Heparin-Induced Thrombocytopenia

Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin

The immunology of PF4 polyanion interactions

Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance

Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia